Inpatient treatment of diabetic patients in Asia

Evidence from India, China, Thailand and Malaysia

J. D. Goldhaber-Fiebert, H. Li, S. Ratanawijitrasin, S. Vidyasagar, X. Y. Wang, Syed Mohamed Al-Junid Syed Junid, N. Shah, Z. Wang, S. Hirunrassamee, K. L. Bairy, J. Wang, Saperi Sulong, A. M. Nur, K. Eggleston

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: The prevalence of Type 2 diabetes mellitus (DM) has grown rapidly, but little is known about the drivers of inpatient spending in low- and middle-income countries. This study aims to compare the clinical presentation and expenditure on hospital admission for inpatients with a primary diagnosis of Type 2 DM in India, China, Thailand and Malaysia. Methods We analysed data on adult, Type 2 DM patients admitted between 2005 and 2008 to five tertiary hospitals in the four countries, reporting expenditures relative to income per capita in 2007. Results Hospital admission spending for diabetic inpatients with no complications ranged from 11 to 75% of per-capita income. Spending for patients with complications ranged from 6% to over 300% more than spending for patients without complications treated at the same hospital. Glycated haemoglobin was significantly higher for the uninsured patients, compared with insured patients, in India (8.6 vs. 8.1%), Hangzhou, China (9.0 vs. 8.1%), and Shandong, China (10.9 vs. 9.9%). When the hospital admission expenditures of the insured and uninsured patients were statistically different in India and China, the uninsured always spent less than the insured patients. Conclusions With the rising prevalence of DM, households and health systems in these countries will face greater economic burdens. The returns to investment in preventing diabetic complications appear substantial. Countries with large out-of-pocket financing burdens such as India and China are associated with the widest gaps in resource use between insured and uninsured patients. This probably reflects both overuse by the insured and underuse by the uninsured.

Original languageEnglish
Pages (from-to)101-108
Number of pages8
JournalDiabetic Medicine
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Malaysia
Thailand
Inpatients
India
China
Health Expenditures
Type 2 Diabetes Mellitus
Therapeutics
Glycosylated Hemoglobin A
Diabetes Complications
Tertiary Care Centers
Diabetes Mellitus
Economics
Health

Keywords

  • Asia
  • Diabetes
  • Economic burden
  • Inpatient treatment

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Goldhaber-Fiebert, J. D., Li, H., Ratanawijitrasin, S., Vidyasagar, S., Wang, X. Y., Syed Junid, S. M. A-J., ... Eggleston, K. (2010). Inpatient treatment of diabetic patients in Asia: Evidence from India, China, Thailand and Malaysia. Diabetic Medicine, 27(1), 101-108. https://doi.org/10.1111/j.1464-5491.2009.02874.x

Inpatient treatment of diabetic patients in Asia : Evidence from India, China, Thailand and Malaysia. / Goldhaber-Fiebert, J. D.; Li, H.; Ratanawijitrasin, S.; Vidyasagar, S.; Wang, X. Y.; Syed Junid, Syed Mohamed Al-Junid; Shah, N.; Wang, Z.; Hirunrassamee, S.; Bairy, K. L.; Wang, J.; Sulong, Saperi; Nur, A. M.; Eggleston, K.

In: Diabetic Medicine, Vol. 27, No. 1, 01.2010, p. 101-108.

Research output: Contribution to journalArticle

Goldhaber-Fiebert, JD, Li, H, Ratanawijitrasin, S, Vidyasagar, S, Wang, XY, Syed Junid, SMA-J, Shah, N, Wang, Z, Hirunrassamee, S, Bairy, KL, Wang, J, Sulong, S, Nur, AM & Eggleston, K 2010, 'Inpatient treatment of diabetic patients in Asia: Evidence from India, China, Thailand and Malaysia', Diabetic Medicine, vol. 27, no. 1, pp. 101-108. https://doi.org/10.1111/j.1464-5491.2009.02874.x
Goldhaber-Fiebert, J. D. ; Li, H. ; Ratanawijitrasin, S. ; Vidyasagar, S. ; Wang, X. Y. ; Syed Junid, Syed Mohamed Al-Junid ; Shah, N. ; Wang, Z. ; Hirunrassamee, S. ; Bairy, K. L. ; Wang, J. ; Sulong, Saperi ; Nur, A. M. ; Eggleston, K. / Inpatient treatment of diabetic patients in Asia : Evidence from India, China, Thailand and Malaysia. In: Diabetic Medicine. 2010 ; Vol. 27, No. 1. pp. 101-108.
@article{8aaae3c0fb3f45c2b6a53576f6ccbf8c,
title = "Inpatient treatment of diabetic patients in Asia: Evidence from India, China, Thailand and Malaysia",
abstract = "Aims: The prevalence of Type 2 diabetes mellitus (DM) has grown rapidly, but little is known about the drivers of inpatient spending in low- and middle-income countries. This study aims to compare the clinical presentation and expenditure on hospital admission for inpatients with a primary diagnosis of Type 2 DM in India, China, Thailand and Malaysia. Methods We analysed data on adult, Type 2 DM patients admitted between 2005 and 2008 to five tertiary hospitals in the four countries, reporting expenditures relative to income per capita in 2007. Results Hospital admission spending for diabetic inpatients with no complications ranged from 11 to 75{\%} of per-capita income. Spending for patients with complications ranged from 6{\%} to over 300{\%} more than spending for patients without complications treated at the same hospital. Glycated haemoglobin was significantly higher for the uninsured patients, compared with insured patients, in India (8.6 vs. 8.1{\%}), Hangzhou, China (9.0 vs. 8.1{\%}), and Shandong, China (10.9 vs. 9.9{\%}). When the hospital admission expenditures of the insured and uninsured patients were statistically different in India and China, the uninsured always spent less than the insured patients. Conclusions With the rising prevalence of DM, households and health systems in these countries will face greater economic burdens. The returns to investment in preventing diabetic complications appear substantial. Countries with large out-of-pocket financing burdens such as India and China are associated with the widest gaps in resource use between insured and uninsured patients. This probably reflects both overuse by the insured and underuse by the uninsured.",
keywords = "Asia, Diabetes, Economic burden, Inpatient treatment",
author = "Goldhaber-Fiebert, {J. D.} and H. Li and S. Ratanawijitrasin and S. Vidyasagar and Wang, {X. Y.} and {Syed Junid}, {Syed Mohamed Al-Junid} and N. Shah and Z. Wang and S. Hirunrassamee and Bairy, {K. L.} and J. Wang and Saperi Sulong and Nur, {A. M.} and K. Eggleston",
year = "2010",
month = "1",
doi = "10.1111/j.1464-5491.2009.02874.x",
language = "English",
volume = "27",
pages = "101--108",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Inpatient treatment of diabetic patients in Asia

T2 - Evidence from India, China, Thailand and Malaysia

AU - Goldhaber-Fiebert, J. D.

AU - Li, H.

AU - Ratanawijitrasin, S.

AU - Vidyasagar, S.

AU - Wang, X. Y.

AU - Syed Junid, Syed Mohamed Al-Junid

AU - Shah, N.

AU - Wang, Z.

AU - Hirunrassamee, S.

AU - Bairy, K. L.

AU - Wang, J.

AU - Sulong, Saperi

AU - Nur, A. M.

AU - Eggleston, K.

PY - 2010/1

Y1 - 2010/1

N2 - Aims: The prevalence of Type 2 diabetes mellitus (DM) has grown rapidly, but little is known about the drivers of inpatient spending in low- and middle-income countries. This study aims to compare the clinical presentation and expenditure on hospital admission for inpatients with a primary diagnosis of Type 2 DM in India, China, Thailand and Malaysia. Methods We analysed data on adult, Type 2 DM patients admitted between 2005 and 2008 to five tertiary hospitals in the four countries, reporting expenditures relative to income per capita in 2007. Results Hospital admission spending for diabetic inpatients with no complications ranged from 11 to 75% of per-capita income. Spending for patients with complications ranged from 6% to over 300% more than spending for patients without complications treated at the same hospital. Glycated haemoglobin was significantly higher for the uninsured patients, compared with insured patients, in India (8.6 vs. 8.1%), Hangzhou, China (9.0 vs. 8.1%), and Shandong, China (10.9 vs. 9.9%). When the hospital admission expenditures of the insured and uninsured patients were statistically different in India and China, the uninsured always spent less than the insured patients. Conclusions With the rising prevalence of DM, households and health systems in these countries will face greater economic burdens. The returns to investment in preventing diabetic complications appear substantial. Countries with large out-of-pocket financing burdens such as India and China are associated with the widest gaps in resource use between insured and uninsured patients. This probably reflects both overuse by the insured and underuse by the uninsured.

AB - Aims: The prevalence of Type 2 diabetes mellitus (DM) has grown rapidly, but little is known about the drivers of inpatient spending in low- and middle-income countries. This study aims to compare the clinical presentation and expenditure on hospital admission for inpatients with a primary diagnosis of Type 2 DM in India, China, Thailand and Malaysia. Methods We analysed data on adult, Type 2 DM patients admitted between 2005 and 2008 to five tertiary hospitals in the four countries, reporting expenditures relative to income per capita in 2007. Results Hospital admission spending for diabetic inpatients with no complications ranged from 11 to 75% of per-capita income. Spending for patients with complications ranged from 6% to over 300% more than spending for patients without complications treated at the same hospital. Glycated haemoglobin was significantly higher for the uninsured patients, compared with insured patients, in India (8.6 vs. 8.1%), Hangzhou, China (9.0 vs. 8.1%), and Shandong, China (10.9 vs. 9.9%). When the hospital admission expenditures of the insured and uninsured patients were statistically different in India and China, the uninsured always spent less than the insured patients. Conclusions With the rising prevalence of DM, households and health systems in these countries will face greater economic burdens. The returns to investment in preventing diabetic complications appear substantial. Countries with large out-of-pocket financing burdens such as India and China are associated with the widest gaps in resource use between insured and uninsured patients. This probably reflects both overuse by the insured and underuse by the uninsured.

KW - Asia

KW - Diabetes

KW - Economic burden

KW - Inpatient treatment

UR - http://www.scopus.com/inward/record.url?scp=73949103811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949103811&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.2009.02874.x

DO - 10.1111/j.1464-5491.2009.02874.x

M3 - Article

VL - 27

SP - 101

EP - 108

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 1

ER -